Experimental MERS treatments enter clinical trial

(NIH/National Institute of Allergy and Infectious Diseases) Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The trial is sponsored by the National Institute of Allergy and Infectious Diseases, part of NIH, and is funded in part by the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary ...